Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients

Novel therapies for sickle cell disease (SCD) based on genetically engineered autologous hematopoietic stem and progenitor cells (HSPCs) are critically dependent on a safe and effective strategy for cell procurement. We sought to assess the safety and efficacy of plerixafor when used in transfused p...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood Adv
Glavni autori: Esrick, Erica B., Manis, John P., Daley, Heather, Baricordi, Cristina, Trébéden-Negre, Hélène, Pierciey, Francis J., Armant, Myriam, Nikiforow, Sarah, Heeney, Matthew M., London, Wendy B., Biasco, Luca, Asmal, Mohammed, Williams, David A., Biffi, Alessandra
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2018
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6177648/
https://ncbi.nlm.nih.gov/pubmed/30282642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016725
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items